Thomas Civik
Chief Executive Officer and Chairman of the Board, Pyxis Oncology, Inc. · United States
Thomas Civik is the CEO of Pyxis Oncology, Inc. (PYXS). Civik is based in the United States.
Biotechnology executive with 17 years at Genentech in oncology roles, serving as Chief Commercial Officer at Foundation Medicine and President & CEO of Five Prime Therapeutics until its $1.9 billion acquisition by Amgen in 2021. Also served as Chairman of ImCheck Therapeutics and Repare Therapeutics.
Recent developments
AI summary of recent coverageRecent coverage has focused on Pyxis Oncology's appointment of Thomas Civik as Chief Executive Officer and Chairman of the Board, effective September 4, 2026. Reports note that Civik received equity compensation in the form of stock options as part of the appointment, and some coverage highlights his prior executive experience at a company that was acquired for $1.9 billion.
Summarized from the headlines below; see each source for the full story.
Our coverage
On CEOInsider
No feature yet. When we publish a feature, interview or cover story on Thomas Civik, it will appear here — and tie into the news timeline.
Thomas Civik: FAQ
- Who is Thomas Civik?
- Thomas Civik is the Chief Executive Officer and Chairman of the Board of Pyxis Oncology, Inc., based in United States.
- What company does Thomas Civik lead?
- Thomas Civik is CEO of Pyxis Oncology, Inc..